Dalbavancin parenteral
- Drugs List
- Therapeutic Indications
- Dosage
- Administration
- Contraindications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
- Monograph
Presentation
Infusions of dalbavancin.
Drugs List
Therapeutic Indications
Uses
Acute bacterial Gram +ve skin and skin structure infections
Dosage
Adults
1.5g dalbavancin administered as one infusion, or as 1g dalbavancin followed one week later by 500mg dalbavancin.
Patients with Renal Impairment
Creatinine clearance less than 30ml/minute and haemodialysis not regular (less than 3 times a week)
1g dalbavancin administered as one infusion, or as 750mg dalbavancin followed one week later by 375mg dalbavancin.
Administration
For intravenous infusion over 30 minutes. Reconstitute and dilute before use.
Contraindications
Children under 18 years
Precautions and Warnings
Severe immunosuppression
Breastfeeding
Moderate hepatic impairment
Pregnancy
Renal impairment - creatinine clearance below 30 ml/minute
Reduce dose in patients with creatinine clearance below 30ml/min
Advise ability to drive/operate machinery may be affected by side effects
Consult national/regional policy on the use of anti-infectives
Use additional systemic antibiotic if anaerobic/resistant bacteria present
Dilute and use as an infusion
Suspend treatment or reduce rate until infusion reactions resolve
Consider pseudomembranous colitis if patient presents with diarrhoea
Superinfection may occur during therapy
Discontinue at once if pseudomembranous colitis occurs
Discontinue if allergic reaction occurs
Pregnancy and Lactation
Pregnancy
Use dalbavancin with caution during pregnancy.
The manufacturer does not recommend using dalbavancin during pregnancy. Animal studies have shown teratogenic effects. Human data is limited and as such a potential risk cannot be ruled out.
Lactation
Use dalbavancin with caution during breastfeeding.
The manufacturer advises that the patient either discontinues dalbavancin or discontinues breastfeeding. Animal data reports significant levels of dalbavancin in the breast milk, however the presence in human breast milk and the effect on exposed infants are unknown. LactMed (2015) suggests that because oral absorption of dalbavancin is poor, an effect on the breastfed infant is unlikely. Monitor the infant for potential effects on the gastrointestinal tract.
Side Effects
"Red man" syndrome (flushing of upper body)
Abdominal discomfort
Abdominal pain
Abnormal liver function tests
Alanine aminotransferase increased
Anaemia
Anaphylactoid reaction
Aspartate aminotransferase increased
Bronchospasm
Candidiasis
Colitis
Constipation
Cough
Decreased appetite
Diarrhoea
Dizziness
Dysgeusia
Dyspepsia
Eosinophilia
Flushing
Fungal infection
Gamma glutamyl transferase (GGT) increased
Headache
Increase in alkaline phosphatase
Increase in lactate dehydrogenase
Increase of liver transaminases
Increased platelet count
Increased uric acid level
Increases in hepatic enzymes
Infusion related reaction
Insomnia
Leucopenia
Nausea
Neutropenia
Ototoxicity
Phlebitis
Pruritus
Pruritus vulvae
Rash
Rise in body temperature
Thrombocytosis
Urinary tract infections
Urticaria
Vomiting
Vulvovaginal infections
Overdosage
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Further Information
Last Full Review Date: August 2019
Reference Sources
Summary of Product Characteristics: Xydalba 500 mg powder for concentrate for solution for infusion. Correvio UK Ltd. Revised December 2018.
US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
Available at: https://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT
Dalbavancin. Last revised: 07 February 2019
Last accessed: 06 August 2019
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.